<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042731</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13004</org_study_id>
    <secondary_id>NCI-3811</secondary_id>
    <secondary_id>NCI-P02-0216</secondary_id>
    <secondary_id>0105</secondary_id>
    <nct_id>NCT00042731</nct_id>
  </id_info>
  <brief_title>Isoflavones &amp; Lycopene in Localized Prostate Ca:Prior to Radical Prostatectomy</brief_title>
  <official_title>A Randomized Pilot Clinical Trial Of The Action Of Isoflavones And Lycopene In Localized Prostate Cancer: Administration Prior To Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Eating a diet rich in isoflavones, compounds found in soy foods, or lycopene, a&#xD;
      substance found in tomatoes, may keep prostate cancer from growing. Giving isoflavones or&#xD;
      lycopene before surgery may be an effective treatment for prostate cancer.&#xD;
&#xD;
      PURPOSE: Randomized clinical trial to compare the effectiveness of isoflavones with that of&#xD;
      lycopene before surgery in treating patients who have stage I or stage II prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the effect of isoflavones vs lycopene prior to radical prostatectomy on&#xD;
           intermediate biomarkers (e.g., indices of cell proliferation and apoptosis) in patients&#xD;
           with localized prostate cancer.&#xD;
&#xD;
        -  Compare the effects of these nutritional supplements on increases in plasma levels and&#xD;
           tissue levels of these agents in these patients.&#xD;
&#xD;
        -  Compare the effects of these nutritional supplements on changes in surrogate markers of&#xD;
           disease progression (e.g., prostate-specific antigen levels) in these patients.&#xD;
&#xD;
        -  Compare the effects of these nutritional supplements on changes in serum steroid&#xD;
           hormones, estradiol, and free testosterone in these patients.&#xD;
&#xD;
        -  Compare the magnitude of these changes in patients treated with these nutritional&#xD;
           supplements vs patients in the control group.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      disease stage (stage I vs stage II) and presence of high-grade prostatic intraepithelial&#xD;
      neoplasia. Patients are randomized to 1 of 7 treatment groups.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 87 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrences of Treatment Effect on Biomarkers in Each Group</measure>
    <time_frame>4 years</time_frame>
    <description>Effect of isoflavones and lycopene on endpoint biomarkers as measured by tissue cell proliferation, apoptosis, or programmed cell death at prostate cancer biopsy and surgical excision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrences of Plasma Level Changes for Each Group</measure>
    <time_frame>4 years</time_frame>
    <description>Plasma levels of isoflavones and lycopene as measured by plasma analysis at baseline and post-study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Tissue Level Increases</measure>
    <time_frame>4 years</time_frame>
    <description>Correlation of plasma and tissue levels of isoflavones and lycopene as measured by plasma and tissue analysis at baseline and post-study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of Disease Progression for Each Group</measure>
    <time_frame>4 years</time_frame>
    <description>Effect of isoflavones and lycopene on markers of disease progression as measured by prostate-specific antigen (PSA) levels at baseline and post-study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of Hormonal Effect</measure>
    <time_frame>4 years</time_frame>
    <description>Effect of isoflavones and lycopene on serum steroid hormones as measured by sex-hormone-binding globulin, estradiol, and free testosterone at baseline and post-study intervention</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Oral isoflavones with multivitamin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohorts I - III: Patients receive 1 of 3 doses of oral isoflavones twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral lycopene with multivitamin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohorts IV-VI: Patients receive 1 of 3 doses of oral lycopene twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple vitamin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lycopene</intervention_name>
    <description>Daily administration as outlined in treatment arm(s)</description>
    <arm_group_label>Oral lycopene with multivitamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamin</intervention_name>
    <description>Daily administration as outlined in treatment arm(s)</description>
    <arm_group_label>Multiple vitamin alone</arm_group_label>
    <arm_group_label>Oral isoflavones with multivitamin</arm_group_label>
    <arm_group_label>Oral lycopene with multivitamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy isoflavones</intervention_name>
    <description>Daily administration as outlined in treatment arm(s)</description>
    <arm_group_label>Oral isoflavones with multivitamin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed localized prostate cancer&#xD;
&#xD;
               -  Stage I or II&#xD;
&#xD;
          -  Scheduled prostatectomy between 4-6 weeks after initial biopsy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  45 to 80&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No known history of hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No known history of renal disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No known history of thyroid disease&#xD;
&#xD;
          -  Body mass index no greater than 32&#xD;
&#xD;
          -  Omnivorous diet&#xD;
&#xD;
          -  No known allergy to study supplements&#xD;
&#xD;
          -  No evidence of prostatitis or urinary tract infection&#xD;
&#xD;
          -  No other prior malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent thyroid hormone replacement medications&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior antibiotics&#xD;
&#xD;
          -  At least 30 days since prior diet high in soy and/or lycopene products (e.g., greater&#xD;
             than 40 mg soy/day and/or greater than 15 mg lycopene/day)&#xD;
&#xD;
          -  No other concurrent nutritional supplements, including modular supplements with other&#xD;
             carotenoids and isoflavones&#xD;
&#xD;
          -  No prior or concurrent therapy for prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagi B. Kumar, PhD, RD, FADA</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Western Regional, Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006-2726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405-6015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - MeritCare Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 21, 2012</last_update_submitted>
  <last_update_submitted_qc>September 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

